PITTSBURGH – Generic drug maker Mylan Laboratories Inc. (MYL) is buying branded drug maker King Pharmaceuticals Inc. (KG) for about $4 billion in stock, company officials said Monday. Mylan has ...

LOS ANGELES – Financier Carl Icahn (search) on Friday offered to buy the shares of generic drugmaker Mylan Laboratories (MYL) that he does not already own for $4.9 billion, or $20 a share, according ...

Celgene sued over proposed Mylan generic of cancer drug New Jersey dismissed case because no Mylan connection to state Court says venue proper where Mylan filed application (Reuters) - Mylan ...

NEW YORK, Feb 1 (Reuters) - Mylan Laboratories Inc. said on Thursday that quarterly profit more than doubled, and reported better-than-expected sales, helped by its generic version of the Ditropan XL ...

PITTSBURGH (AP) -- One of the world's largest generic drug makers, Mylan Laboratories Inc., will buy King Pharmaceuticals Inc. for $4 billion in stock as Mylan makes a stronger foray into the branded ...

Mylan Laboratories said on Monday it agreed to acquire troubled drugmaker King Pharmaceuticals Inc. for about $4 billion, adding patent-protected brand drugs to Mylan’s generic-drug offerings. Under ...

Pittsburgh-based Mylan Labs will purchase 71.5% of the shares of Hyderabad, India-based Matrix Labs for about $736 million. Matrix will remain a publicly traded company in India and will continue to ...

Billionaire investor Carl Icahn has dropped his $5.39 billion offer to buy Mylan Laboratories Inc. and tendered his shares after regulators opened an investigation of a Mylan pain patch that was ...

Mylan Laboratories Inc. (MYL) Q1 2010 Earnings Call April 29, 2010 10:00 AM ETExecutivesDan Crookshank - VP, Global IRRobert Coury - Chairman & ...

SAN FRANCISCO (MarketWatch) -- Mylan Laboratories Inc. and Forest Laboratories Inc.'s Forest Laboratories Holdings Ltd. said late Wednesday they have entered into an agreement for the ...

SAN FRANCISCO (MarketWatch) -- Mylan Laboratories Inc. said Wednesday it will reorganize following its acquisition of a controlling interest in Matrix Laboratories. The company said Chief Scientific ...